Searched for
CIPLA SUPPLY DISRUPTION
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analystsAs the old saying goes: Nothing can be ruled out on the street. Which means that one should be prepared for anything. Now, what is the prob...- India raises price cap on cancer drugs to tackle shortageIndia's drug price regulator has increased the ceiling prices of cancer drugs cisplatin and carboplatin by 50% to tackle shortages caused b...
- Indian cancer patients battle shortage of key drugs as platinum costs surgeCancer patients in India are struggling to find essential platinum-based drugs. A surge in global platinum prices and supply chain issues a...
- Geopolitical stability will decide market’s next move: Sandip SabharwalIndian equity markets are holding above 24,000, buoyed by improving sentiment and steady earnings, though geopolitical tensions remain a co...
- These large-caps have ‘strong buy’ & ‘buy’ recos and an upside potential of up to 25%Here’s a thing investors in equity need to keep in mind. A large part of the upmove one might see in the next one or two trading sessions w...
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...
- Most hated stocks: FIIs dumping these 146 companies without a break for 4 straight quarters. Do you own any?Foreign institutional investors have been consistently selling shares in 146 Indian companies for four consecutive quarters. This selling s...
- Cipla shares slide 5% after temporary halt in key drug manufacturingCipla shares fell sharply on Friday after a halt in Lanreotide Injection production due to USFDA observations at its Greek partner. Supply ...
- Cipla Q3 preview: Up to 7% YoY uptick seen in revenue. Margins to fall on a YoY and sequential basisCipla's Q3FY25 revenue is expected to grow 3.1-7%, with profit estimates ranging from a 2.2% decline to 14% growth. Brokerages have differi...
- Have we missed the bulk of the comeback rally in pharma stocks? Nithya Balasubramanian answers“Sun, Cipla, Lupin being market leaders, should be able to do well. Most of these companies have actually added on the Street last year. Wh...
- Pills to wellness, Cipla is seeking a new identityOne of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was made possi...
- Pills to wellness, Cipla is seeking a new identityOne of the major successes of Hamied was building a strong US business, despite Cipla being a late entrant. Hamied said this was possible b...
- Pharma Inc takes a giant digital leap with ABCD TechLeading pharma companies Sun Pharma, Lupin, Cadila Healthcare, Torrent Pharma, Dr Reddy’s Labs and Cipla have come together to invest in a ...
- Indian pharmaceutical firms go local for APIs, seeking to end reliance on ChinaThough India is known as the pharmacy of the world for its massive production capacities of both generic drugs and vaccines, China accounte...
- Remdesivir shortage in Maharashtra public hospitalsState governments typically coordinate drug orders for public hospitals, where most Covid-19 patients are treated. In some states, includin...
- No Chinese supply threat for drug companies, but scaling Great Wall is tough“The concerns over supply of Chinese raw material proved to be ill-founded,” Nilesh Gupta, managing director of Lupin, told ET.
- Cipla's Q4 results could set the tone for what to expect from its peers for the quarterThe company, aspiring to become a lung leader globally, could not escape the impact of coronavirus.
- Q4 earning preview: Pharma pack up for good show, may go unscathed from virus hitInvestors may keenly follow Sun Pharma earnings for updates on Halol OAI.
- Buy Cipla, target price Rs 523: Nirmal BangTthe brokerage has downward revised its FY21 and FY22 forecasts on Cipla, having knocked off Voltaren sales number and pushed Albuterol inh...
- Inventory buffer to keep pharma healthy for now“Right now, we are good on supplies, but obviously it cannot continue indefinitely,” Sharma added.
Load More
